We are live on ! Find out more

Amplify Weight Loss Drug & Treatment ETF

THNR

Market cap $5.64M

24.50 USD

-0.24

0.97%

At close Updated Oct 16, 4:00 PM EDT

1 day

-0.97%

5 days

-0.08%

1 month

-2.27%

3 months

-5.15%

6 months

-1.49%

Year to date

-3.62%

1 year

3.24%

5 years

-3.54%

10 years

-3.54%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 40%

Neutral 60%

Negative 0%

From Laggard to Leader: The Surprising Comeback of Healthcare

Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.

From Laggard to Leader: The Surprising Comeback of Healthcare

Zacks Investment Research

Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.

Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

Who Are You Calling Passive? Many Index ETFs Dynamically Rebalanced in September

There is a myth that index-based ETFs are all static buy-and-hold products that passively track a benchmark. Many people think of indexing through the lens of market-cap strategies like the Vanguard S&P 500 ETF (VOO).

Who Are You Calling Passive? Many Index ETFs Dynamically Rebalanced in September

NTHM's Index Rebalance Puts Thematic Rotation to Work

The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP-1 weight loss drug manufacturers and midstream energy join the index, while battery technology & storage and software-as-a-service (SaaS) exit.

NTHM's Index Rebalance Puts Thematic Rotation to Work

THNR's Weight-Loss Index Swaps Hims & Hers for Gilead

The Amplify Weight Loss Drug & Treatment ETF (THNR) just refreshed its holdings to keep pace with where the weight-loss drug race is heading. Its underlying index, the VettaFi Weight Loss Drug & Treatment Index (THINR), completed a scheduled rebalance on Sept.

THNR's Weight-Loss Index Swaps Hims & Hers for Gilead

Inside THNR: A Leaner Approach to Weight Loss Investing

Demand for GLP-1 weight loss drugs has reshaped the healthcare industry. And ETFs such as the Amplify Weight Loss Drug & Treatment ETF (THNR) give investors a way to access this growing market.

Inside THNR: A Leaner Approach to Weight Loss Investing

Zacks Investment Research

Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Zacks Investment Research

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

LLY Clears Major Obesity Trial: Get Exposure in THNR

Weight loss drugs have been a big growth area in pharmaceuticals since GLP-1s hit the scene. This booming market has also breathed new life into companies like Eli Lilly (LLY), turning the stock into a must-have for many equity holdings.

LLY Clears Major Obesity Trial: Get Exposure in THNR

See News Rankings

Price charts implemented using Lightweight Charts™